| Detailed information |
|---|
| CancerLivER ID | 2322 |
| Biomarker | Myc |
| Biomarker Name/Symbol (given in Publication) | Myc |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Strong predictor for RFS in late-recurring (>1 year) and validated on independent dataset |
| Experimental Condition | early occurrence v/s late recurrence |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upegulated in HCC than non-tumor |
| Level of significance | NA |
| Source | Tissue |
| PMID | 20380719 |
| Type of Biomarker | Prognostic |
| Pathway | Cell cycle progression, apoptosis and cellular transformation |
| Cohort | 90 HCV-associated HCC patients; 44 Nontumoral HCC; 8 metastatic liver tumors |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV associated HCC |
| Year of Publication | 2010 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT03253289,NCT02939807,NCT03738111,NCT03245190 |